Mayer Davidson to Thiazolidinediones
This is a "connection" page, showing publications Mayer Davidson has written about Thiazolidinediones.
Connection Strength
3.664
-
Davidson MB. The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
Score: 0.729
-
Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018 Jan; 135:102-110.
Score: 0.611
-
Davidson MB. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications. 2016 08; 30(6):981-5.
Score: 0.548
-
Hsia SH, Navar MD, Duran P, Shaheen M, Davidson MB. Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
Score: 0.398
-
Davidson MB. Clinical implications of the DREAM Study. Diabetes Care. 2007 Feb; 30(2):418-20.
Score: 0.290
-
Tran MT, Navar MD, Davidson MB. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care. 2006 Jun; 29(6):1395-6.
Score: 0.276
-
Davidson MB. Thiazolidinediones. N Engl J Med. 2005 Jan 13; 352(2):205-7; author reply 205-7.
Score: 0.251
-
Roy R, Navar M, Palomeno G, Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care. 2004 Jul; 27(7):1741-2.
Score: 0.242
-
Davidson MB. Twice-Daily NPH or mixture insulins versus triple therapy: apples versus oranges: response to Poulsen et al. Diabetes Care. 2004 Jul; 27(7):1846; author reply 1847-8.
Score: 0.242
-
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008 Jan; 31(1):173-5.
Score: 0.077